Targets and Emerging Therapies for Schizophrenia (ePub)
(Sprache: Englisch)
New and emerging directions in pharmaceutical research to
better treat schizophrenia
Although the dopamine hypothesis has been the cornerstone of
schizophrenia therapeutics, it is clear that dopamine-based
approaches do not treat all aspects of the...
better treat schizophrenia
Although the dopamine hypothesis has been the cornerstone of
schizophrenia therapeutics, it is clear that dopamine-based
approaches do not treat all aspects of the...
sofort als Download lieferbar
eBook (ePub)
170.99 €
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenloser tolino webreader
Produktdetails
Produktinformationen zu „Targets and Emerging Therapies for Schizophrenia (ePub)“
New and emerging directions in pharmaceutical research to
better treat schizophrenia
Although the dopamine hypothesis has been the cornerstone of
schizophrenia therapeutics, it is clear that dopamine-based
approaches do not treat all aspects of the disease. Moreover, many
schizophrenia patients fail to respond to current antipsychotics.
Integrating chemistry, biology, and pharmacology, this book
explores emerging directions in pharmaceutical research for drug
targeting and discovery in order to find more effective treatments
for schizophrenia, one of the most serious and widespread
psychiatric diseases.
Targets and Emerging Therapies for Schizophrenia presents
the basics of schizophrenia, drug targets for the disease, and
potential new drugs and therapeutics. It begins with a discussion
of prevalence and etiology. Then, it describes therapies such as
dopamine agonists and phosphodiesterase (PDE) inhibitors as well as
growing research aimed at addressing untreated symptoms. Next, the
authors discuss receptor modulators, inhibitors, and targeting
strategies for drug discovery. Both the neurobiological and
chemical aspects of all major pharmacological targets are
examined.
With contributions from an international team of pioneering
pharmaceutical researchers, this book compiles the current
knowledge in the field, setting the stage for new breakthroughs in
the treatment of schizophrenia. Targets and Emerging Therapies
for Schizophrenia:
* Provides a comprehensive resource for neuro-drug discovery and
the development of molecular targets for schizophrenia
treatment
* Draws from chemistry, biology, and pharmacology for more
effective drug targeting and discovery
* Explores a wide range of receptors and molecular targets,
including dopamine, PDEs, and neuropeptides
With Targets and Emerging Therapies for Schizophrenia as
their guide, drug discovery and development scientists have the
information they need to advance their own research so that new,
more effective treatments for schizophrenia will soon be a
reality.
better treat schizophrenia
Although the dopamine hypothesis has been the cornerstone of
schizophrenia therapeutics, it is clear that dopamine-based
approaches do not treat all aspects of the disease. Moreover, many
schizophrenia patients fail to respond to current antipsychotics.
Integrating chemistry, biology, and pharmacology, this book
explores emerging directions in pharmaceutical research for drug
targeting and discovery in order to find more effective treatments
for schizophrenia, one of the most serious and widespread
psychiatric diseases.
Targets and Emerging Therapies for Schizophrenia presents
the basics of schizophrenia, drug targets for the disease, and
potential new drugs and therapeutics. It begins with a discussion
of prevalence and etiology. Then, it describes therapies such as
dopamine agonists and phosphodiesterase (PDE) inhibitors as well as
growing research aimed at addressing untreated symptoms. Next, the
authors discuss receptor modulators, inhibitors, and targeting
strategies for drug discovery. Both the neurobiological and
chemical aspects of all major pharmacological targets are
examined.
With contributions from an international team of pioneering
pharmaceutical researchers, this book compiles the current
knowledge in the field, setting the stage for new breakthroughs in
the treatment of schizophrenia. Targets and Emerging Therapies
for Schizophrenia:
* Provides a comprehensive resource for neuro-drug discovery and
the development of molecular targets for schizophrenia
treatment
* Draws from chemistry, biology, and pharmacology for more
effective drug targeting and discovery
* Explores a wide range of receptors and molecular targets,
including dopamine, PDEs, and neuropeptides
With Targets and Emerging Therapies for Schizophrenia as
their guide, drug discovery and development scientists have the
information they need to advance their own research so that new,
more effective treatments for schizophrenia will soon be a
reality.
Inhaltsverzeichnis zu „Targets and Emerging Therapies for Schizophrenia (ePub)“
Preface vii Contributors xi Introduction 1 Alan J. Cross 1 Dopaminergic Hypothesis of Schizophrenia: A Historical Perspective 5 Aurelija Jucaite and Svante Nyberg 2 Dopamine D2/D3 Partial Agonists as Antipsychotics 37 Philip G. Strange 3 D1/D5 Dopamine Agonists as Pharmacotherapy for Schizophrenia 51 Kevin N. Boyd and Richard B. Mailman 4 Phosphodiesterase Inhibitors as a Novel Therapeutic Approach for Schizophrenia 85 Judith A. Siuciak and William J. Pitts 5 Glutamatergic Synaptic Dysregulation in Schizophrenia 115 Joseph T. Coyle, Alo Basu, and Michael Benneyworth 6 Metabotropic Glutamate 2/3 Receptor Agonists and Positive Allosteric Modulators of Metabotropic Glutamate Receptor 2 as Novel Agents for the Treatment of Schizophrenia 143 Gerard J. Marek, Bruce J. Kinon, David L. McKinzie, Jeffrey M. Schkeryantz, and James A. Monn 7 AMPA Receptor Positive Modulators 187 John A. Morrow, John K.F. Maclean, and Craig Jamieson 8 Progress in the Exploration and Development of GlyT1 Inhibitors for Schizophrenia 233 Jeffrey S. Albert and Michael W. Wood 9 Combined Dopamine D2 and 5-Hydroxytryptamine (5-HT)1A Receptor Strategies for the Treatment of Schizophrenia: A Pharmacological and Chemical Perspective 255 Andrew C. McCreary, Roelof W. Feenstra, and Caitlin A. Jones 10 5-HT2C and 5-HT6 Receptor Targeted Emerging Approaches in Schizophrenia 273 Sharon Rosenzweig-Lipson, John Dunlop, Lee E. Schechter, Thomas A. Comery, Jonathan Gross, and Karen L. Marquis 11 The Cholinergic Hypothesis: An Introduction to the Hypothesis and a Short History 295 Joseph I. Friedman, Isabella Kanellopoulou, and Vladan Novakovic 12 alpha7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia 319 Mihály Hajós and Bruce N. Rogers 13 Muscarinic Acetylcholine Receptors as Novel Targets for the Development of Therapeutics for Schizophrenia 355 Christian C. Felder, David L. McKinzie, Richard C. Thompson, and Bin Liu 14 Will Modulation of Neuropeptide Receptors Produce the Next Generation
... mehr
of Antipsychotic Drugs? A Focus on the Neurokinin and Neurotensin Systems 381 Lee A. Dawson, Paul W. Smith, and Jeannette M. Watson 15 GABA and Schizophrenia 425 John H. Kehne and George D. Maynard Index 469
... weniger
Autoren-Porträt von Jeffrey S. Albert
JEFFREY S. ALBERT, PhD, is a Project Leader and Head ofLead Generation Chemistry in AstraZeneca's neuroscience department.
He has authored or coauthored more than forty publications, mostly
focusing on novel therapeutic targets involved in depression,
schizophrenia, and Alzheimer's disease and on the development and
application of fragment-based lead generation methodologies.
MICHAEL W. WOOD, PhD, is an External Collaborations
Director in AstraZeneca's neuroscience unit where he is responsible
for coordinating research to deliver novel therapeutics targeting
schizophrenia as well as other neuroscience treatments. He has been
focused on neuroscience drug discovery research for fifteen
years.
Bibliographische Angaben
- Autor: Jeffrey S. Albert
- 2012, 1. Auflage, 486 Seiten, Englisch
- Herausgegeben: Jeffrey S. Albert, Michael W. Wood
- Verlag: John Wiley & Sons
- ISBN-10: 1118309405
- ISBN-13: 9781118309407
- Erscheinungsdatum: 06.06.2012
Abhängig von Bildschirmgröße und eingestellter Schriftgröße kann die Seitenzahl auf Ihrem Lesegerät variieren.
eBook Informationen
- Dateiformat: ePub
- Größe: 6.77 MB
- Mit Kopierschutz
Sprache:
Englisch
Kopierschutz
Dieses eBook können Sie uneingeschränkt auf allen Geräten der tolino Familie lesen. Zum Lesen auf sonstigen eReadern und am PC benötigen Sie eine Adobe ID.
Kommentar zu "Targets and Emerging Therapies for Schizophrenia"
0 Gebrauchte Artikel zu „Targets and Emerging Therapies for Schizophrenia“
| Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
|---|
Schreiben Sie einen Kommentar zu "Targets and Emerging Therapies for Schizophrenia".
Kommentar verfassen